These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3768240)

  • 21. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A comparison of alpha 1-acid glycoprotein (AAG) concentration and disopyramide binding in Chinese and Japanese].
    Jin EZ
    Hokkaido Igaku Zasshi; 1999 Jul; 74(4):279-88. PubMed ID: 10480035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in human plasma by capillary electrophoresis.
    Jabor VA; Lanchote VL; Bonato PL
    Electrophoresis; 2001 Apr; 22(7):1406-12. PubMed ID: 11379964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.
    Baruzzi A; Contin M; Perucca E; Albani F; Riva R
    Eur J Clin Pharmacol; 1986; 31(1):85-9. PubMed ID: 3780833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantioselective binding of disopyramide to alpha1-acid glycoprotein and its variants.
    Kishino S; Itoh S; Nakagawa T; Miyazaki K
    Eur J Clin Pharmacol; 2001 Oct; 57(8):583-7. PubMed ID: 11758636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
    Belpaire FM; Bogaert MG
    Int J Clin Pharmacol Ther Toxicol; 1991 Mar; 29(3):96-102. PubMed ID: 2071261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
    Toy W; Sasyniuk BI
    J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding of disopyramide to alpha 1-acid glycoprotein in plasma measured by competitive equilibrium dialysis.
    Norris RL; Ahokas JT; Ravenscroft PJ; Henry M
    J Pharm Sci; 1984 Jun; 73(6):824-6. PubMed ID: 6737271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
    Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
    Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered protein binding of disopyramide in plasma from patients with cancer and with inflammatory disease.
    Echizen H; Saima S; Umeda N; Ishizaki T
    Ther Drug Monit; 1987 Sep; 9(3):272-8. PubMed ID: 3672569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.
    Nakagawa T; Kishino S; Itoh S; Sugawara M; Miyazaki K
    Br J Clin Pharmacol; 2003 Dec; 56(6):664-9. PubMed ID: 14616427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
    Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP
    Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.